Format
Sort by

Send to

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 1037

1.

[PI3K and mTOR pathway and molecular targeted agents].

Nishio K, Sakai K, Togashi Y.

Nihon Rinsho. 2015 Aug;73(8):1315-22. Review. Japanese.

PMID:
26281684
2.

[A Case of Effective Whole-Brain Irradiation and Lapatinib/Capecitabine Combination Therapy for HER2-Positive Breast Cancer with Multiple Brain Metastases].

Shibasaki M, Tanabe A, Toda T, Sakata H, Ijichi M, Kusaka K, Bandai Y.

Gan To Kagaku Ryoho. 2015 Jun;42(6):755-7. Japanese.

PMID:
26199252
3.

MMP9, Cyclin D1 and β-Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro.

Umbreit C, Erben P, Faber A, Hofheinz RD, Aderhold C, Weiss C, Hoermann K, Wenzel A, Schultz JD.

Anticancer Res. 2015 Jul;35(7):3801-10.

PMID:
26124325
4.

Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells.

Jin HO, Hong SE, Kim CS, Park JA, Kim JH, Kim JY, Kim B, Chang YH, Hong SI, Hong YJ, Park IC, Lee JK.

Toxicol Appl Pharmacol. 2015 Aug 15;287(1):17-25. doi: 10.1016/j.taap.2015.05.001. Epub 2015 May 14.

PMID:
25981168
5.

Dual HER2 blockade: preclinical and clinical data.

Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G.

Breast Cancer Res. 2014 Aug 1;16(4):419. doi: 10.1186/s13058-014-0419-5. Review. Erratum in: Breast Cancer Res. 2014;16(6):468.

6.

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S, Shepherd LE, Dent S, Ellard SL, Tonkin K, Pritchard KI, Whelan TJ, Nomikos D, Nusch A, Coleman RE, Mukai H, Tjulandin S, Khasanov R, Rizel S, Connor AP, Santillana SL, Chapman JA, Parulekar WR.

J Clin Oncol. 2015 May 10;33(14):1574-83. doi: 10.1200/JCO.2014.56.9590. Epub 2015 Mar 16.

7.

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.

Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE; TEACH Investigators.

Eur J Cancer. 2015 Apr;51(6):685-96. doi: 10.1016/j.ejca.2015.02.005. Epub 2015 Mar 6.

PMID:
25752740
8.

Sensitive single quadrupole LC/MS method for determination of lapatinib in human plasma.

Musijowski J, Filist M, Rudzki PJ.

Acta Pol Pharm. 2014 Nov-Dec;71(6):1029-36.

9.

On and off metronomic oral vinorelbine in elderly women with advanced breast cancer.

De Iuliis F, Salerno G, Taglieri L, Lanza R, Scarpa S.

Tumori. 2015 Jan-Feb;101(1):30-5. doi: 10.5301/tj.5000207. Epub 2015 Feb 5.

PMID:
25702645
10.

Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.

Lorenzen S, Riera Knorrenschild J, Haag GM, Pohl M, Thuss-Patience P, Bassermann F, Helbig U, Weißinger F, Schnoy E, Becker K, Stocker G, Rüschoff J, Eisenmenger A, Karapanagiotou-Schenkel I, Lordick F.

Eur J Cancer. 2015 Mar;51(5):569-76. doi: 10.1016/j.ejca.2015.01.059. Epub 2015 Feb 16.

PMID:
25694417
11.

Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience.

Carli P, Militello L, Miolo GM, Quitadamo D, Lombardi D, Torrisi E, Scalone S, Crivellari D, Spazzapan S.

Tumori. 2014 Nov-Dec;100(6):605-11. doi: 10.1700/1778.19260.

PMID:
25688493
12.

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

Lopez-Chavez A, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CC, Abdullaev Z, Xi L, Pack S, Meltzer PS, Corless CL, Sandler A, Beadling C, Warrick A, Liewehr DJ, Steinberg SM, Berman A, Doyle A, Szabo E, Wang Y, Giaccone G.

J Clin Oncol. 2015 Mar 20;33(9):1000-7. doi: 10.1200/JCO.2014.58.2007. Epub 2015 Feb 9.

13.

[Systemic treatment of brain metastases from breast cancer].

Taillibert S, Conforti R, Bonneterre J, Bachelot T, Le Rhun E, Bernard-Marty C.

Cancer Radiother. 2015 Feb;19(1):36-42. doi: 10.1016/j.canrad.2014.12.003. Epub 2015 Feb 7. Review. French.

PMID:
25662600
14.

Phase I study of cisplatin, hyperthermia, and lapatinib in patients with recurrent carcinoma of the uterine cervix in a previously irradiated area.

van Meerten E, Franckena M, Wiemer E, van Doorn L, Kraan J, Westermann A, Sleijfer S.

Oncologist. 2015 Mar;20(3):241-2. doi: 10.1634/theoncologist.2014-0365. Epub 2015 Feb 6.

15.

A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.

Deeken JF, Wang H, Subramaniam D, He AR, Hwang J, Marshall JL, Urso CE, Wang Y, Ramos C, Steadman K, Pishvaian MJ.

Cancer. 2015 May 15;121(10):1645-53. doi: 10.1002/cncr.29224. Epub 2015 Jan 29.

16.

[Efficacy of lapatinib versus trastuzumab in neoadjuvant therapy of HER-2 positive breast cancer: a meta-analysis].

Jiang Z, Yang Y, Pan Z, Yue Z, Li L.

Zhonghua Yi Xue Za Zhi. 2014 Dec 30;94(48):3854-8. Chinese.

PMID:
25623322
17.

Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer.

Zhang L, Ngo JA, Wetzel MD, Marchetti D.

Neoplasia. 2015 Jan;17(1):101-13. doi: 10.1016/j.neo.2014.11.007.

18.

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V.

J Clin Oncol. 2015 May 10;33(14):1564-73. doi: 10.1200/JCO.2014.57.1794. Epub 2015 Jan 20.

19.
20.

Targeting HER2 for the treatment of breast cancer.

Rimawi MF, Schiff R, Osborne CK.

Annu Rev Med. 2015;66:111-28. doi: 10.1146/annurev-med-042513-015127. Review.

PMID:
25587647
Items per page

Supplemental Content

Write to the Help Desk